Efficacy of Daylight as Adjunctive Treatment in Patients With Depression

Status Terminated

Clinical Trial Summary

The aim of this study is to improve the treatment effect for outpatients with depression by adding regular daily morning daylight exposure to their treatment with antidepressants. Patients will wear a personal light tracker to keep them motivated. Our hypothesis is that patients daily exposed to morning daylight, as a supplement to standard treatment for depression, will achieve significantly higher antidepressant effect that patients receiving standard treatment alone. Furthermore, we hypothesize that they will experience improved well-being and sleep.

Clinical Trial Description

Due to inadequate efficiency of existing medical and psychotherapeutic treatments for depression there is a need for investigating the efficacy of adjunctive treatments. Light therapy has proven efficient as an add-on treatment for depression, but some patients might prefer being outdoors rather than sitting in front of a light therapy screen. However, no high-quality studies, have so far investigated the antidepressant and other potential positive effects of regular exposure to morning daylight for patients with unipolar depression. The aim of this study is to examine the efficacy of morning daylight as add-on to treatment as usual in patients with depression. Efficacy is measured as reduction of depressive symptoms, improvement of sleep quality, and improvement of well-being. Methods and material: A randomized controlled trial comprising 150 patients diagnosed with unipolar depression aged 18-50 years will be conducted. Patients are included after giving informed consent and the study period is 6 weeks. A wearable Personal Light Tracker, measuring the amount off light received, will be provided for all participants. Participants will be randomized into the following groups: Group 1: Daylight (outdoor daylight exposed stay for minimum 30 minutes per day before 1 pm). To motivate patients to go outside they will receive psychoeducation on the connection between exposure to morning daylight and a possible antidepressant effect, and they are introduced to potential options for outdoor activities. A detailed instruction to the personal light tracker and the matching app, for monitoring the amount of light received throughout the day, is provided. Group 2: Control group receiving treatment as usual. Patients will wear a personal light tracker but they are not introduced to the light-monitoring-app. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04712968
Study type	Interventional
Source	University of Aarhus
Contact
Status	Terminated
Phase	N/A
Start date	September 1, 2021
Completion date	June 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03256162` - Ketamine as an Adjunctive Therapy for Major Depression	Phase 1
Recruiting	`NCT05570110` - Enoxolone in Major Depression - Biomarker-outcome Relationship	Phase 1/Phase 2
Completed	`NCT02530164` - Transcranial Direct Current Stimulation (tDCS) As Treatment for Major Depression	N/A
Completed	`NCT00964054` - Depression Outcomes Study of Exercise	Phase 1
Completed	`NCT01447602` - A Clinical Trial of IPT-A to Prevent Suicide in Depressed Adolescents With Suicidal Behavior	Phase 3
Completed	`NCT00517387` - The Effects of Quetiapine XR on Cognition, Mood and Anxiety Symptoms in SSRI-Resistant Unipolar Depression	Phase 3
Recruiting	`NCT04939649` - Ketamine as an Adjunctive Therapy for Major Depression (2)	Phase 3
Recruiting	`NCT05894980` - How to Reduce Suicidal Thoughts and Impulsivity in Depression	N/A
Enrolling by invitation	`NCT04717921` - Assesment of Retinal Nerve Fiber Layer in First Episode Depressive Patients Using Selective Serotonin Reuptake Inhibitor
Recruiting	`NCT03358056` - Effects of Mindfulness Based Cognitive Therapy on Emotional Processing	N/A
Recruiting	`NCT03711019` - Efficacy of Convulsive Therapies During Continuation	N/A
Completed	`NCT02111915` - Thinking Healthy Program - Peer Delivered (Pakistan)	N/A
Completed	`NCT02104232` - Thinking Healthy Program - Peer Delivered, India (THPP-I)	N/A
Terminated	`NCT01219686` - EScitalopram PIndolol ONset of Action	Phase 2/Phase 3
Completed	`NCT00158990` - Triiodothyronine (T3) Supplementation in the Treatment of Bipolar and Unipolar Depression.	Phase 3
Completed	`NCT01049347` - Amitriptyline and Paroxetine Treatment of Major Depression	Phase 3
Completed	`NCT03268434` - Evaluation of Metacognitive Training for Depression (D-MCT) in Outpatient Care	N/A
Completed	`NCT01880957` - PET and MRI Brain Imaging of Bipolar Disorder	N/A
Completed	`NCT04420793` - Voice Changes During ECT
Not yet recruiting	`NCT01694030` - Effects of Repeated Attachment Security Priming on Depressed Mood: a Clinical Study	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.